Definium Therapeutics Stock Forecast

Stock Price Forecast

The 3 analysts with 12-month price forecasts for Definium Therapeutics stock have an average target of 30.33, with a low estimate of 25 and a high estimate of 36. The average target predicts an increase of 73.81% from the current stock price of 17.45.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$25	$30.33	$30	$36
Change	+43.27%	+73.81%	+71.92%	+106.30%

Analyst Ratings

The average analyst rating for Definium Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26
Strong Buy	1	1
Buy	1	2
Hold	0	0
Sell	0	0
Strong Sell	0	0
Total	2	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Rudy Li Wolfe Research	Wolfe Research	Buy Initiates $25	Buy	Initiates	$25	+43.27%	Feb 24, 2026
Andrew Tsai Jefferies	Jefferies	Strong Buy Initiates $30	Strong Buy	Initiates	$30	+71.92%	Jan 30, 2026
Brian Abrahams RBC Capital	RBC Capital	Buy Maintains $20 → $36	Buy	Maintains	$20 → $36	+106.30%	Jan 23, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

36.13M

EPS This Year

-1.91

from -2.06

EPS Next Year

-1.72

from -1.91

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	-	-	-	36.13M
Revenue Growth	-	-	-	-	-	-	-
EPS	-3.40	-1.84	-2.44	-1.54	-2.06	-1.91	-1.72
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	15	13

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	200.0M
Avg	n/a	36.1M
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-1.60	-0.54
Avg	-1.91	-1.72
Low	-2.21	-2.26

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.